معرفی
Gail Stanley, MD, MPH, is an Instructor in Pulmonary, Critical Care & Sleep Medicine at Yale School of Medicine. She specializes in treating cystic fibrosis and multidrug-resistant infections, employing bacteriophage therapy as a key innovation. Her research focuses on phage therapy applications for CF and bronchiectasis, with affiliations to the Center for Phage Biology and Therapy. Dr. Stanley completed her MD at the University of Colorado School of Medicine, an MPH at Tufts, and her residency in Internal Medicine at the University of New Mexico. She holds a fellowship in Pulmonary and Critical Care Medicine from Yale School of Medicine.
Education:
- B.A., Biochemistry & Molecular, Cellular & Developmental Biology, University of Colorado (undated)
- M.P.H., Tufts University (2010)
- M.D., University of Colorado School of Medicine (2014)
Research Interests: Dr. Stanley’s work centers on bacteriophage therapy for drug-resistant bacterial infections, particularly Pseudomonas aeruginosa and Achromobacter. She explores phage cocktails, synergistic treatments with zinc porphyrins, and optimized phage preparation pipelines. Her clinical focus includes managing CF-related lung infections and extrapulmonary acute lung injury mechanisms. Collaborations within the Koff Laboratory and with institutions like the Center for Phage Biology and Therapy drive her translational research.
Articles Overview: Recent work spans phage therapy efficacy studies, EGFR’s role in lung injury, and multidrug-resistant infection management. Key themes include innovative antimicrobial strategies, cytokine regulation in inflammation, and hyperoxia-induced lung pathology.
Advising & Grants: While specific grants aren’t detailed, her publications suggest funding for phage therapy research. She collaborates with colleagues like Jon Koff, Paul Turner, and Govind Rajagopalan on NIH-funded projects.
Labs & Teams: Active in the Koff Laboratory and the Center for Phage Biology and Therapy at Yale, advancing clinical and preclinical phage studies.